IOL Chemicals & Pharmaceuticals Ltd
- P/E
- 30x
- 52-week range
- 67.19 – 224
- ROE
- 8%
- ROCE
- 11%
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
IOL Chemicals and Pharmaceuticals Limited is engaged in manufacturing and selling of pharmaceutical and chemical products. The Company operates through two segments: Chemical and Pharmaceutical. The Chemical segment produces and sells Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride, Mono Chloro Acetic Acid, Para Amino Phenol (PAP), and others. The Pharmaceutical segment produces and sells various active pharma ingredients (API) including Ibuprofen, Metformin, Fenofibrate, Lamotrigine, Clopidogrel Bisulphate, Pantoprazole, Gabapentin, Paracetamol, and others. Its API product portfolio includes Pantoprazole Sodium, Clopidogrel Bisulphate (Form II), Losartan Potassium, Levetiracetam, and Fenofibrate (Micronised). Its Specialty Chemical division includes Ethyl Acetate, Iso Butyl Benzene, Mono Chloro acetic Acid, and Acetic Anhydride. Its Ethyl Acetate is used in industries like flexible packaging, pharmaceuticals, ink, food processing, pesticides, and the paint industry.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →IOL Chemicals & Pharmaceuticals Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)30 against a typical 34.3: cheaper than most peers (1st = cheapest).100th of 220
- Sales growth+37% against a typical +15.6% from a year earlier.43rd of 197
- Profit growth+88.2% against a typical +18.9% from a year earlier.35th of 160
- Share price, 3 months+22.4% against a typical −0.5%.31st of 200
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE A+ | Stable | 6 Jul 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 6 Jul 2026 | Reaffirmed | CARE A+ | — | CARE | ₹ 700 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 10 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 20 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 11 Feb 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2025 and to consider declaration of Interim Dividend for FY 2025-26 |
| 11 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 7 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 16 May 2025 | Financial Results | To consider and approve the financial results for the period ended March 31, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 545 | 520 | 504 | 502 | 526 | 523 | 528 | 552 | 568 | 580 | 619 | 756 |
| Expenses | 481 | 476 | 454 | 452 | 484 | 476 | 465 | 490 | 510 | 523 | 527 | 653 |
| Operating Profit | 64 | 44 | 50 | 51 | 42 | 47 | 63 | 62 | 57 | 57 | 93 | 104 |
| OPM % | 12% | 9% | 10% | 10% | 8% | 9% | 12% | 11% | 10% | 10% | 15% | 14% |
| Other Income | 7 | 8 | 8 | 7 | 6 | 4 | 5 | 7 | 7 | −6 | 2 | 8 |
| Interest | 4 | 4 | 3 | 2 | 4 | 4 | 4 | 4 | 3 | 4 | 3 | 4 |
| Depreciation | 16 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 20 | 20 | 20 | 21 |
| Profit before tax | 51 | 32 | 38 | 39 | 26 | 28 | 45 | 46 | 41 | 28 | 71 | 87 |
| Tax % | 26% | 28% | 25% | 24% | 26% | 26% | 30% | 25% | 26% | 25% | 25% | 26% |
| Net Profit | 38 | 23 | 28 | 30 | 19 | 21 | 32 | 34 | 30 | 21 | 53 | 64 |
| EPS in Rs | 1.29 | 0.79 | 0.96 | 1.01 | 0.65 | 0.7 | 1.08 | 1.16 | 1.02 | 0.7 | 1.81 | 2.2 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 15%
- 5 Years
- 3%
- 3 Years
- 2%
- TTM
- 19%
- 10 Years
- 19%
- 5 Years
- −20%
- 3 Years
- 2%
- TTM
- 68%
- 10 Years
- 19%
- 5 Years
- 7%
- 3 Years
- 30%
- TTM
- —
- 10 Years
- 18%
- 5 Years
- 9%
- 3 Years
- 8%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| IOL Chemicals & Pharmaceuticals Ltd | ₹ 180.40 | — | 30x | — | 8% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 53.4x | 11.1x | 0% | 0% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 114.5x | 32.1x | 0% | 0% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 64.8x | 14.7x | 0% | 0% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 38.5x | 5.2x | 0% | 0% |
| Coromandel International | ₹ 1,723.60 | ₹ 50,876 Cr. | 28x | 4.5x | 0% | 0% |
Management
- Pardeep Kumar Khanna
- Chief Financial Officer
- Abhay Raj Singh
- Senior Vice President, Company Secretary
- Varinder Gupta
- Managing Director, Executive Director
- Vikas Gupta
- Joint Managing Director, Executive Director
- Abhiraj Gupta
- Executive Director
- Kushal Kumar Rana
- Director - Works, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.